A shadow economy for unlicensed weight-loss drugs is being driven by TikTok fitness influencers and vendors on messaging platforms, based on new investigations.
Experimental Treatment Gaining Popularity Via Social Media
Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed fat-burning properties. Viewers are encouraged to contact these profiles privately for source information, while also receiving discount codes.
Active Commerce on Messaging Platforms
Additionally, a robust market exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and claims of next-day UK delivery. Sellers market the drug there before directing buyers to other platforms for purchases.
Understanding Retatrutide
Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic.
Healthcare Experts Express Concerns
Nevertheless, doctors and pharmacists have warned that the distribution of what is still an unapproved drug in the United Kingdom is worrisome and could lead to users administering products of uncertain source.
Several professionals stated the demand for retatrutide could be connected to the rising cost of approved weight loss treatments such as Mounjaro.
Legal Status and Enforcement
Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.
Some influencers attempt to circumvent the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still violate medicines, marketing, and customer regulations, potentially leading to penalties, prosecution or imprisonment.
Service Reaction and Content Elimination
According to TikTok, the service has removed violative material and prohibited associated keywords and search suggestions. The organization said it was dedicated to keeping the platform secure and allocating resources in enhancing compliance measures.
Online Trading Operations
Investigations also found groups with up to nine thousand participants selling retatrutide using the platform's built-in discovery tool, which functions like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, filled with photos of weight loss, positive testimonials and detailed guides for mixing or injecting at residence.
Within minutes of joining one community, a vendor posted WhatsApp details, where the majority of transactions occur. The vendor provided an guidebook and guaranteed shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None asked about body mass, health issues or past usage.
Product Information and Pricing
Inside these communities, posts display black plastic packages with postal service stickers, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with sterile water, or ready-to-use pens usually sold at 160 pounds for 20mg. When asked how much time a injector should be used, sellers give contradictory responses varying between a few weeks to “depends on your body”.
Service Oversight and Security Measures
A representative for the messaging service stated it actively monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“Individuals are injecting substances they cannot confirm. Even if the research behind retatrutide is valid, these online products may not contain what they advertise,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the surge in interest to recent cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the conditions they were produced in was sterile,” she explained.
Her team has already encountered patients harmed by self-injection from unverified suppliers. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These materials could be contaminated or improperly measured.”
Producer Statement
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company investigational substance not yet approved … may expose users to potentially significant medical dangers”.
